Sign in
TerminatedPhase 4

Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance

Key facts

Who runs it
Stadtspital Zürich
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 4
People taking part
13 people enrolled
Started
10 Oct 2023
Ended
31 Dec 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Furosemide
  • Metolazone
  • Acetazolamide
Record updated
14 February 2025
Why it stopped
Low recruitment in both centers

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Elective or emergency hospital admission with clinical diagnosis of acute heart failure
  • One or more clinical signs of volume overload (i.e., peripheral edema, pleural effusion, jugular venous distension)
  • Low diuretic efficacy in the first 2 hours after the standard screening dose Furosemide i.v. (i.e., urine volume < 300 ml and urine sodium concentration < 70 mmol/L)
  • Plasma N terminal-proBNP level at enrolment > 1000 ng/L
  • Signed Informed Consent form

Who cannot take part

  • Maintenance treatment with Acetazolamide or Metolazone
  • Concurrent diagnosis of acute coronary syndrome requiring urgent revascularization
  • Severe chronic kidney disease (estimated glomerular filtration rate < 15 ml/min/1.73 m2) or use of renal replacement therapy at any time before study inclusion
  • History of cardiac transplantation or ventricular assist device
  • Allergy, intolerance or other contraindication against one of the study drugs
  • Use of any non-protocol defined diuretic agent that cannot be stopped upon study inclusion except for sodium-glucose co-transporter-2 inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin) and mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone)
  • Age below 18 years
  • Systolic blood pressure < 90 mmHg
  • Expected use of intravenous vasopressors (e.g., noradrenaline, adrenaline), inotropes (e.g., dobutamine, milrinone, levosimendan) at any time point during the study
  • Severe liver dysfunction or cirrhosis at risk of hepatic encephalopathy
  • Severe electrolyte disturbances or metabolic acidosis requiring specific intravenous treatment
  • Pregnancy or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The P-VALUE-AHF trial is a multicenter, randomized, open-label, parallel-group trial on the diuretic and decongestive effects of different diuretic escalation strategies in patients with acute heart failure and diuretic resistance.

Read full original descriptionShow less

The main aims are

* to compare the diuretic efficacy of three therapeutic strategies in patients with acute heart failure and diuretic resistance. * to assess the improvement in clinical congestion and to compare the symptom-relief among the different treatment regimens

The 3 groups in the trial

  • group FFExisting treatment, for comparison

    Group FF will receive a doubled dose Furosemide i.v. The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v. Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection.

    Treatment: Furosemide

  • group FMExisting treatment, for comparison

    Group FM will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v. Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection. Metolazone will be administered orally.

    Treatment: Furosemide and Metolazone

  • group FAExisting treatment, for comparison

    Group FA will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v. Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection. Acetazolamide (500mg) will be administered intravenously as a short infusion.

    Treatment: Furosemide and Acetazolamide

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance (P-Value-AHF): A Multicentre, Randomized, Parallel-group, Open-label Trial
Record updated
14 February 2025